Our results suggest that RORα activators could provide a good strategy for the development of effective therapeutics for liver diseases mediated by the IL-6Rα–STAT3 axis, such as hepatic injury with APR and hepatocellular carcinoma. Here, IL6R is linked to hepatocellular carcinoma.